Oral Semaglutide Projected to Reduce Major Cardiovascular Events 14% in High-Risk T2D Adults

Individuals with type 2 diabetes (T2D) face a significantly elevated risk of atherosclerotic cardiovascular disease (ASCVD), which remains a leading cause of morbidity and mortality. Despite advancements in glycemic control, a substantial residual cardiovascular risk persists, particularly in those with established ASCVD or chronic kidney disease. Current standard-of-care often falls short in comprehensively addressing both metabolic and cardiovascular outcomes. GLP-1 receptor agonists (GLP-1RAs) like semaglutide have demonstrated cardiovascular benefits, but the real-world impact of oral formulations in broad, high-risk populations needs further quantification to inform clinical guidelines and public health strategies.

Researchers conducted a projection analysis using data from the National Health and Nutrition Examination Survey (NHANES) cycles (1988-2018) to estimate the impact of oral semaglutide on major adverse cardiovascular events (MACE) in high-risk U.S. adults with type 2 diabetes (T2D). The analysis identified NHANES participants eligible for oral semaglutide based on the SOUL randomized clinical trial criteria (T2D with established ASCVD and/or chronic kidney disease). The study then applied the 14% MACE risk reduction observed in the SOUL trial to this eligible NHANES population, modeling potential real-world outcomes and the projected number of events avoided over a defined period.

The analysis projected a significant reduction in major adverse cardiovascular events (MACE) among high-risk U.S. adults with type 2 diabetes (T2D) eligible for oral semaglutide. Based on the 14% relative risk reduction observed in the SOUL trial, the implementation of oral semaglutide therapy in this population is estimated to prevent a substantial number of MACE over a five-year period. This projection underscores the potential for oral semaglutide to translate its clinical trial benefits into meaningful public health impact, particularly in a demographic with high cardiovascular burden. The findings suggest that targeting this specific high-risk group with oral semaglutide could lead to a tangible decrease in cardiovascular morbidity. The NHANES data provided a robust real-world context for these projections, reflecting the diversity and prevalence of T2D and ASCVD in the U.S. population. The consistency of the projected benefit across various demographic subgroups further supports the broad applicability of these findings. This analysis provides a compelling case for the widespread adoption of oral semaglutide in appropriate patient populations. The projection indicated that oral semaglutide could reduce the incidence of major adverse cardiovascular events by 14% in high-risk U.S. adults with type 2 diabetes.